# US 2016/0354378 A1 · Composition for Preventing and Treating Acetaminophen Inducing Hepatotoxicity Containing TNP(N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine) as an Effective Ingredient

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354378 A1
- Document ID: US20160354378A1
- Status: Published application
- Kind: A1
- Application number: 15/032,295
- Filed: 2015-07-03
- Published: 2016-12-08
- Earliest claimed: 2015-02-13
- Assignees: Korea Advanced Institute of Science and Technology
- Applicants: Korea Advanced Institute of Science and Technology
- Inventors: Seyun KIM; Yong-Mahn HAN; Young-Ran KIM; Seulgi LEE
- Web page: https://patentgrep.com/patent/US20160354378A1

## CPC

- A61K 31/52: Purines, e.g. adenine
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 13/12: of the kidneys
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a composition for the prevention and treatment of liver toxicity originated from acetaminophen comprising TNP (N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine) as an active ingredient. The present inventors confirmed that TNP known as a 5-inosito pyrophosphate inhibitor suppressed apoptosis caused by acetaminophen in human embryonic stem cell-derived liver cells, mouse liver cells, and human hepatoma cell lines, up-regulated glutathione converted in liver cells, and inhibited JNK phosphorylation that is a kind of response against stress increased by acetaminophen. The inventors further confirmed that TNP had the activity of protecting liver cells from the toxicity caused by acetaminophen in an animal model. Therefore, TNP can be efficiently used as an active ingredient for a composition for the prevention and treatment of liver toxicity caused by acetaminophen.

## Claims

### Claim at position 1

1-17. (canceled)

### Claim 18

A method for treating liver toxicity comprising the step of administering a pharmaceutically effective dose of TNP (N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine) or a pharmaceutically acceptable salt thereof to a subject in need of treatment.

### Claim 19 (depends on 18)

The method for treating liver toxicity according to claim 18, wherein said TNP is the compound represented by the following formula 1:

### Claim 20 (depends on 18)

The method for treating liver toxicity according to claim 18, wherein said TNP suppresses apoptosis caused by acetaminophen (AP).

### Claim 21 (depends on 19)

The method for treating liver toxicity according to claim 19, wherein said TNP increases the level of glutathione (GSH) in liver cells.

### Claim 22 (depends on 18)

The method for treating liver toxicity according to claim 18, wherein said TNP suppresses a stress response increased by acetaminophen.

### Claim 23

A method for treating liver disease comprising the step of administering a pharmaceutically effective dose of TNP (N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine) or a pharmaceutically acceptable salt thereof to a subject in need of treatment.

### Claim 24 (depends on 23)

The method for treating liver disease according to claim 23, wherein the liver disease is selected from the group consisting of fulminant hepatic failure, liver necrosis, nephrotoxicity, and liver cirrhosis.
